At the same time the Federal Trade Commission today announced it would challenge the $2 billion proposed purchase of rival drugmaker Mayne Pharma, an Australian company with U.S. headquarters in Paramus, N.J., by Lake Forest, Ill.-based Hospira, the FTC unveiled an agreement in which the two companies would divest Barr Pharmaceuticals within 10 days of the deals closing and sell assets used to manufacture five generic injectable drugs. The FTC alleged that the acquisition violated Section 7 of the Clayton Act and Section 5 of the FTC Act, and would lessen competition and create a monopoly for the five drugs. The purchase was announced in September 2006. -- by Mark Taylor
FTC wants Hospira deal altered
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.